Predicted to enable ubiquitin conjugating enzyme activity. Predicted to be involved in protein K48-linked ubiquitination; protein monoubiquitination; and ubiquitin-dependent protein catabolic process. Orthologous to human UBE2R2 (ubiquitin conjugating enzyme E2 R2); INTERACTS WITH acetamide; bisphenol A; gentamycin.
hypothetical protein LOC689226; LOC689226; similar to ubiquitin-conjugating enzyme E2R 2; ubiquitin-conjugating enzyme E2 R2; uncharacterized protein LOC689226
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of UBE2R2 protein]
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of UBE2R2 protein] and [Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of UBE2R2 protein
2-bromopalmitate inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of UBE2R2 protein] and [Cadmium Chloride results in increased abundance of Cadmium] which results in increased palmitoylation of UBE2R2 protein
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2R2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2R2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of UBE2R2 mRNA